Table 1.
Clinical characteristics of patients of the two groups.
| Parameters | Sitagliptin group (n = 137) | Conventional group (n = 137) | P value |
|---|---|---|---|
| Age (years) | 63.8 ± 9.7 | 63.6 ± 1.0 | 0.90 |
| Gender (males) (%) | 83 (61) | 82 (60) | 1.00 |
| Body mass index | 25.0 ± 4.3 | 25.0 ± 3.8 | 0.88 |
| Current smoking | 30 (22) | 29 (21) | 0.22 |
| Duration of diabetes (years) | 17.2 ± 8.5 | 17.3 ± 8.7 | 0.94 |
| HbA1c at baseline (mmol/mol) | 64.9 ± 11.9 | 63.9 ± 10.6 | 0.45 |
| Systolic blood pressure (mmHg) | 130 ± 16 | 132 ± 14 | 0.88 |
| Total cholesterol at baseline (mmol/l) | 5.02 ± 0.91 | 4.94 ± 0.86 | 0.50 |
| HDL cholesterol at baseline (mmol/l) | 1.46 ± 0.37 | 1.39 ± 0.38 | 0.14 |
| Triglyceride at baseline (mmol/l) | 1.13 (0.83, 1.55) | 1.17 (0.90, 1.72) | 0.22 |
| eGFR (ml/min/1.73 m2) | 77.7 ± 21.2 | 79.7 ± 24.2 | 0.47 |
| Mean IMT (mm) | 0.84 ± 0.19 | 0.84 ± 0.21 | 0.81 |
| Right maximum IMT (mm) | 1.04 ± 0.29 | 1.06 ± 0.40 | 0.69 |
| Left maximum IMT (mm) | 1.10 ± 0.32 | 1.11 ± 0.41 | 0.87 |
| Use of oral glucose-lowering agents | |||
| Metformin | 49 (36) | 48 (35) | 1.00 |
| Sulfonylurea | 17 (12) | 15 (11) | 0.85 |
| Glinides | 2 (1) | 19 (14) | <0.001 |
| Thiazolidinediones | 13 (9) | 11 (8) | 0.83 |
| α-Glucosidase inhibitor | 41 (30) | 42 (31) | 1.00 |
| Others | |||
| Angiotensin-converting enzyme inhibitors | 8 (6) | 4 (3) | 0.59 |
| Angiotensin II receptor blockers | 53 (39) | 69 (50) | 0.07 |
| Statins | 66 (48) | 63 (46) | 0.81 |
| Antiplatelet agents | 29 (21) | 30 (22) | 1.00 |
Data are number (%) of patients or mean ± SD values.
IMT, intima-media thickness; eGFR, glomerular filtration rate.